Beyond the targeted therapies mentioned above, inhibition of AKT or ERK might coordinate with HLA-G-based therapies, as HLA-G/ILT-4 has been shown to promote tumor cell proliferation, migration, and invasion through the activation of AKT/ERK signaling in CRC [105]. The gene discussed is AKT1; the disease is neoplasm.